The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System.
Sam HarperMuralikrishnan R KarthaStuart MealingMaurizio PavanelloLuigi BonavinaPublished in: PharmacoEconomics - open (2024)
Introduction of RefluxStop as a GERD treatment option in Italy is likely to be associated with substantial clinical benefits and a marginal budget impact.